575 related articles for article (PubMed ID: 19508669)
41. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
[TBL] [Abstract][Full Text] [Related]
42. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution.
Dumont LJ; Cancelas JA; Graminske S; Friedman KD; Vassallo RR; Whitley PH; Rugg N; Dumont DF; Herschel L; Siegal AH; Szczepiorkowski ZM; Fender L; Razatos A
Transfusion; 2013 May; 53(5):972-80. PubMed ID: 22882530
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.
Cid J; Escolar G; Lozano M
Vox Sang; 2012 Nov; 103(4):322-30. PubMed ID: 22563850
[TBL] [Abstract][Full Text] [Related]
44. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5CPD Erythro-Sol opti system.
Högman CF; Eriksson L; Wallvik J; Payrat JM
Vox Sang; 1997; 73(4):212-9. PubMed ID: 9407638
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
[TBL] [Abstract][Full Text] [Related]
46. Preparation, storage and quality control of platelet concentrates.
Tynngård N
Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
[TBL] [Abstract][Full Text] [Related]
47. [The efficacy and safety of autologous cryopreserved platelet transfusion in management of thrombocytopenia after chemotherapy in hematological malignancy].
Liu GQ; Ding HF; Lu XJ; Xu M; Xing J; Zhao X; Han F; Shang YH
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):188-91. PubMed ID: 22781890
[TBL] [Abstract][Full Text] [Related]
48. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation.
Dijkstra-Tiekstra MJ; van de Watering LM; Rondeel JM; Slomp J; de Wildt-Eggen J
Transfus Med; 2014 Apr; 24(2):99-104. PubMed ID: 24506143
[TBL] [Abstract][Full Text] [Related]
49. Quality assessment of platelets stored in a modified platelet additive solution with trehalose at low temperature (10 °C) and in vivo effects on rabbit model of thrombocytopenia.
Wang X; Fan Y; Shi R; Li J; Zhao S
Platelets; 2015; 26(1):72-9. PubMed ID: 24499059
[TBL] [Abstract][Full Text] [Related]
50. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies.
Eriksson L; Shanwell A; Gulliksson H; Högman CF; Svensson LA; Kristensen J; Berg B
Vox Sang; 1993; 64(3):133-8. PubMed ID: 8484245
[TBL] [Abstract][Full Text] [Related]
51. Age of platelet concentrates and time to the next transfusion.
Caram-Deelder C; van der Bom JG; Putter H; Leyte A; Kerkhof DV; Evers D; Beckers EA; Weerkamp F; Hudig F; Zwaginga JJ; Rondeel JMM; de Vooght KMK; Péquériaux NCV; Visser O; Wallis JP; Middelburg RA
Transfusion; 2018 Jan; 58(1):121-131. PubMed ID: 29090466
[TBL] [Abstract][Full Text] [Related]
52. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
[TBL] [Abstract][Full Text] [Related]
53. [Morphology and function of platelets stored in modified platelet additive solution at low temperature].
Wang X; Shi RH; Li J; Liu FJ; Chen HM; Zhao SM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):797-801. PubMed ID: 19549411
[TBL] [Abstract][Full Text] [Related]
54. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation.
Li G; Liu F; Mao X; Hu L
Transfus Apher Sci; 2011 Aug; 45(1):21-4. PubMed ID: 21798807
[TBL] [Abstract][Full Text] [Related]
55. An audit of platelet transfusion within the Wellington Cancer Centre.
Buhrkuhl DC; Karlsson MK; Carter JM
Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
[TBL] [Abstract][Full Text] [Related]
56. Current status of additive solutions for platelets.
Alhumaidan H; Sweeney J
J Clin Apher; 2012; 27(2):93-8. PubMed ID: 22298435
[TBL] [Abstract][Full Text] [Related]
57. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.
Drawz SM; Marschner S; Yañez M; García de Coca A; Feys HB; Deeren D; Coene J
Transfusion; 2015 Jul; 55(7):1745-51. PubMed ID: 25702711
[TBL] [Abstract][Full Text] [Related]
58. Preparation of leucocyte-poor platelet concentrates from buffy coats. IV. Clinical evaluation.
Pietersz RN; Reesink HW; Huijgens PC; van Oers MH
Vox Sang; 1988; 55(3):129-32. PubMed ID: 3070936
[TBL] [Abstract][Full Text] [Related]
59. Effects of storage time on quantitative and qualitative platelet function after transfusion.
Rosenfeld BA; Herfel B; Faraday N; Fuller A; Braine H
Anesthesiology; 1995 Dec; 83(6):1167-72. PubMed ID: 8533908
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
